Fig. 4: Effect of later G-CSF initiation on CRS severity in G-CSF naïve patients treated with anti-CD19 CAR T cells for lymphoma.

A Among 34 lymphoma patients with grade ≥1 CRS who had not previously received G-CSF, the cumulative incidence of grade ≥2 CRS was estimated from the time of onset of grade 1 CRS, stratified by whether patients received G-CSF within 7 days after grade 1 CRS onset (N = 17) or not (N = 17). 95% confidence intervals are represented by shading.